Systematic review and Meta-analysis on efficacy and safety of berberine for dyslipidemia.
10.19540/j.cnki.cjcmm.20190626.501
- Author:
Ying ZHAO
1
;
Yuan-Yuan YANG
1
;
Ya-Wei DU
1
;
Hui-Min YANG
1
;
Sheng-Xian WU
1
Author Information
1. Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Beijing 100700, China.
- Publication Type:Systematic Review
- Keywords:
Meta-analysis;
berberine;
dyslipidemia;
efficacy;
safety;
systematic review
- MeSH:
Berberine/therapeutic use*;
Dyslipidemias/drug therapy*;
Humans;
Hypolipidemic Agents/therapeutic use*;
Lipids;
Randomized Controlled Trials as Topic
- From:
China Journal of Chinese Materia Medica
2020;45(3):664-673
- CountryChina
- Language:Chinese
-
Abstract:
To evaluate the clinical efficacy and safety of berberine in the treatment of dyslipidemia. In this review, CNKI, WanFang, VIP, CBM, PubMed, Cochrane Library, EMbase, and Medline(OVID) were retrieved from database establishment to January, 2019 in any language. Randomized controlled trials(RCTs) of berberine with or without lipid-lowering drugs vs placebo, without drugs or lipid-lowering drugs only in treatment of dyslipidemia were collected. Data extraction and paper quality assessment were conducted according to the Cochrane Handbook. Then RevMan 5.3 software was used for Meta-analysis. A total of 25 trials were included, covering 3 042 cases, including 1 552 cases in the experimental group and 1 490 cases in the control group. The clinical heterogeneity of the included trials was relatively high, and the methodological quality of most trials was generally low, with bias in terms of random sequence generation, allocation hiding, blind method and result data. Interventions were divided into different subgroups for analysis. Meta-analysis suggested that use berberine alone or along with lipid lowing drugs could reduce TC, TG, LDL-C levels and increased HDL-C levels with statistically significant difference as compared with control group. As compared with control group, there was no statistically significant difference in the incidence of adverse events. No severe adverse effects were reported in all trials. Berberine has good efficacy and safety in the treatment of dyslipidemia. Due to the quality limitations of the included trials, the above conclusions need to be further verified by high-quality, large sample size and multi-center clinical trials.
